Read the results of the scientific studies supporting BeniCaros:
29 June 2020
cRG-I selectively modulates human gut microbiota while promoting gut barrier integrity (van den Abbeele et al., 2020)
Pre-clinical study demonstrating that BeniCaros can modulate beneficial gut microbiota, improve gut barrier integrity, and decreased inflammatory markers.
15 March 2021
Effect of Rhamnogalacturonan-I on Anti-Viral Response in Healthy Subjects (Lutter et al., 2021) (abstract)
Clinical study in healthy adults showing that prophylactic intake of BeniCaros, as a dietary supplement, modulated immune responses to rhinovirus infection and decreased duration and severity of symptoms without any side effects. Abstract presented and published at American Thoracic Society (ATS) , full manuscript is currently in preparation.
16 March 2021
“Development of an affordable, sustainable and efficacious plant-based immunomodulatory food ingredient based on bell pepper or carrot RG-I pectic polysaccharides” (McKay et al., 2021)
Clinical and pre-clinical studies demonstrating that dietary supplementation with BeniCaros is safe and effective, and has a dual mode of action: direct 1) immunomodulatory effect on phagocytosis and 2) gut microbiota modulation with enhanced production of beneficial microbial metabolites (short-chain fatty acids).
23 December 2021
“Consistent Prebiotic Effects of Carrot RG-I on the Gut Microbiota of Four Human Adult Donors in the SHIME® Model despite Baseline Individual Variability” (van den Abbeele et al. 2021)
This study demonstrated that administration of cRG-I consistently modified the human microbiota despite the inherent interindividual variability between subjects. Levels of metabolites such as short-chain fatty acids (SCFA) that exert a beneficial effect on gut and immune health were increased as a result of the microbiota modulation. This study thus further confirms the dual mode of action of cRG-I on the host immune system and gut microbiota.
24 December 2021
“The Dietary Intake of Carrot-Derived Rhamnogalacturonan-I Accelerates and Augments the Innate Immune and Anti-Viral Interferon Response to Rhinovirus Infection and Reduces Duration and Severity of Symptoms in Humans in a Randomized Trial” (Lutter et al., 2021)
Pivotal clinical study showing that Nutrileads’ proprietary carrot-derived Rhamnogalacturonan-I (cRG-I) fiber, accelerates protective anti-viral immune responses and reduces symptoms after an experimental infection with common cold virus in humans.